Skip to search formSkip to main contentSkip to account menu

KMD 3213

Known as: KMD-3213 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
BACKGROUND Silodosin (KMD-3213), a highly selective α1a-adrenergic receptor antagonist, was approved in Japan (2006), the United… 
2006
2006
The duration of action of Silodosin (KMD-3213) against the phenylephrine-induced increase in intraurethral pressure in urethane… 
2005
2005
Coordination Failure Diagnostics (CFD) is a model that analyses real market processes with the help of time pattern analysis and… 
2004
2004
We examined reserpine‐induced chemical denervation supersensitivity with special reference to alpha‐1 adrenoceptor (AR) subtypes… 
Review
2004
Review
2004
KMD 3213 [silodosin, KAD 3213] is an orally active alpha(1)-adrenoceptor antagonist under development with Kissei (Japan) for the… 
2004
2004
Sympathetic efferent nerves are present in tendons, but their function within tendon is unknown. alpha(1)-Adrenoceptors are… 
2004
2004
We established three human embryonic kidney (HEK) 293 cell lines stably expressing alpha(1)-adrenoceptor (AR) subtypes, one… 
2002
2002
KMD-3213 ((-)-1-(3-hydroxypropyl)-5-((2R)-2-[[2-([2-[(2,2,2-trifluoroethyl)oxy]phenyl]oxy)ethyl]amino]propyl)-2,3-dihydro-1H… 
1999
1999
Subtypes of α1‐adrenoceptor in rabbit iris have been examined in functional, binding and molecular biological experiments. In…